Expanded biomarker analysis from faktion: fulvestrant + capivasertib vs. Fulvestrant + placebo after relapse or progression on an AI in ER+ mBC

5-year follow-up of ELEVATE-TN: acalabrutinib ± obinutuzumab vs. obinutuzumab + chlorambucil in TN CLL

Single agent PD-1 blockade as curative-intent treatment in dMMR-LARC

Biomarker analysis by NGS from SOLAR-1: Alpelisib + fulvestrant in HR+, HER2- ABC patients

Results of DESTINY-Breast04: Trastuzumab deruxtecan vs. TPC for HER2-low unresectable and/or mBC

MAINTAIN: ET with or without ribociclibafter progression on AET + CDK4/6i in patients with unresectable or HR+, HER2- mBC

PALOMA-2: OS of 1L treatment with palbociclib + letrozole vs. placebo + letrozole in women with ER+, HER2- ABC

SHINE: Primary results of ibrutinib in combination with bendamustine-rituximab and rituximab maintenance in untreated MCL